Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations

    Ze-Bo Jiang
    Ze-Bo Jiang
    Chun Xie
    Chun Xie
    Xia Li
    Xia Li
    Liping Liu
    Liping Liu
    Xiao-Jun Yao
    Xiao-Jun Yao

    Oncology reports, 2016.

    Cited by: 0|Bibtex|Views1|Links
    WOS

    Abstract:

    EGFR and KRAS mutations are the two most common driver mutations in non-small cell lung cancer (NSCLC). Molecular target-based therapy using small molecules such as gefitinib has been used for inhibiting EGFR with good initial responses; however, drug resistance is common when using a mono-targeting strategy. At present, KRAS remains an u...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments